Quarterly results round-up: a mixed bag for PerkinElmer and S&N
This article was originally published in Clinica
Executive Summary
Healthcare and life sciences firm PerkinElmer has grown its top line by 14% to $479.5m during its second fiscal quarter, but has seen its profit half to $28.6m. The dip in income was mainly due to a pre-tax gain of $25.6m during last year's Q2, related to the purchase of the remaining stake in a joint venture with Danaher's AB Sciex business. Adjusted earnings were up 27% during the most recent quarter, to $0.42 per share.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.